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Abstract The 85-kDa cytosolic PLA2 (cPLA2) is present in 
many cells and tissues and its unusual functional properties and 
catalytic mechanism are being elucidated. Notably, cPLA2 
becomes catalytically active in the presence of free Ca2+ 
concentrations as present in stimulated cells and preferentially 
cleaves arachidonic acid-containing phospholipids. A variety of 
agonists, growth factors and cytokines, as well as stressful 
stimuli activate cPLA2 to hydrolyze cellular phospholipids 
thereby liberating fatty acids and lysophospholipids and provid-
ing the precursor substrates for the biosynthesis of eicosanoids 
and platelet-activating factor. These products of cPLA2 
contribute to inflammatory and degenerative disease states and 
cPLA2 is therefore an attractive target for the development of 
novel therapies. 
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1. Introduction 
Phospholipases A2 (PLA2s) are ubiquitous enzymes that 
are present in most cells and tissues. Hydrolysis of cellular 
phospholipids by PLA2s causes release of free fatty acids 
with concomitant formation of lysophospholipids. The newly 
released free fatty acids may affect cellular functions, since 
they activate protein kinase C [1] and MAP kinases [2,3] 
and the concomitantly generated lysophospholipids may cause 
damage to cellular membranes [4]. The products of PLA2 
catalyzed phospholipid hydrolysis include arachidonic acid 
and lyso-PAF, which are the precursors of a wide spectrum 
of pro-inflammatory mediators (including prostaglandins, 
thromboxanes, leukotrienes and PAF) [5,6]. Once formed 
these lipid mediators may act as intracellular messengers act-
ing on protein targets in the cell where they have been formed 
or, alternatively, they may leave the cell and interact with 
specific receptors on the cell surface of the parent and/or 
neighboring cells. The release of arachidonic acid, formation 
of the intermediate metabolite (endoperoxide or hydroperox-
ide) and conversion to the final eicosanoid can take place in 
two separate cell types [7]. Many of the newly generated lipids 
derived from products of PLA2 action have profound biolog-
ical properties. They promote inflammatory reactions and 
participate in processes that lead to tissue injury. PLA2s are 
therefore attractive targets for the development of inhibitors 
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that may be useful novel therapeutic agents for the treatment 
of inflammatory and degenerative diseases. 
2. The PLA2 subfamilies 
Using functional criteria for classification, one can distin-
guish at least four different subfamilies of PLA2 enzymes. 
First, secretory PLA2s (sPLA2s) that have a molecular mass 
of 14 kDa and are characterized by a catalytic requirement for 
Ca2+ and a rigid three-dimensional structure maintained by 
disulfide bridges. Two mammalian sPLA2s (referred to as 
group I and II) have been purified, cloned and extensively 
characterized over the last two decades [8] and two genes 
encoding two additional mammalian sPLA2s have recently 
been identified [9]. Second, an 85 kDa Ca2+-sensitive cytosolic 
PLA2 (cPLA2) has been purified, cloned and biochemically 
characterized [10,11]. The structural and biochemical proper-
ties of cPLA2 are very different from those of the other well-
known PLA2s and will be discussed in detail below. Third, 
several distinct Ca2+-independent cytosolic PLA2 activities 
(iPLA2s) with molecular masses ranging from 29 to 85 kDa 
have been purified from different tissues and cellular sources. 
Although the biochemical properties of these iPLA2s have 
been extensively characterized [12], to date only the primary 
structure of the CHO cell-derived iPLA2 has been delineated 
and it is noteworthy that it has no structural relationship to 
cPLA2 [13]. Fourth, the important features that differentiate 
the PAF acetylhydrolases (PAF-AHs) from the above de-
scribed PLA2s is their remarkable specificity for short and/ 
or oxidized acyl groups at the sn-2 position of phospholipids 
and their Ca2+ independence [14]. A PAF-AH present in plas-
ma where it is bound to lipoproteins (and therefore also re-
ferred to as lipoprotein-associated PLA2) has been purified 
and cloned. Several intracellular PAF-AHs have been purified 
from brain and the cloned cDNAs of three isoforms encode 
two catalytic subunits (|3 and y) with molecular masses of 30 
and 29 kDa, respectively, and a regulatory (a) subunit of 45 
kDa. There is no sequence homology between the extracellu-
lar and intracellular PAF-AH [14]. 
3. The cPLA2 gene 
The Ca2+-sensitive cytosolic PLA2 (cPLA2) was first char-
acterized in platelets and macrophage cells [10,11]. The cDNA 
of cPLA2 was subsequently cloned from macrophage cell li-
braries [10,11,15] and the promoter of the cPLA2 gene was 
isolated [16-18]. Collectively, the data showed that the cPLA2 
cDNA comprised a total of 2880 nucleotides, including about 
200 nucleotides for the 5'-untranslated region and about 500 
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Fig. 1. Protein sequence similarity between cPLA2 from six species. The cPLA2 protein sequences deduced from the DNA sequences of six dif-
ferent species [11,25] are compared using the GCG program plotsimilarity. A similarity score of 1.5 indicates perfect conservation within a local 
region. The locations of the CaLB domain, the 'hinge' region, the catalytically essential residues (R-200, S-228 and D-549), the critical cysteine 
residue (C-331) and the two conserved phosphorylation sites (S-505 and S-727) are indicated. 
nucleotides for the 3'-untranslated region. While the complete 
chromosomal DNA for cPLA2 has not yet been sequenced, 
there appear to be at least 7 introns, and some features of the 
genetic control mechanisms of the cPLA2 gene were revealed 
by analysis of its 5' flanking sequence [16-18]. Additional 
regulation appears to be mediated post-transcriptionally [19]. 
The genomic location of cPLA2 and useful associated variable 
markers have been identified [17,20]. A CA repeat appears 160 
bases upstream from the transcriptional start site, in both the 
rat and human 5' flanking regions [17,18,20]. The study of this 
dinucleotide repeat allowed for the mapping of the cPLA2 
gene to rat chromosome 13 [20]. Another heterozygosity in 
the human 5' flanking region, the poly-A segment of a partial 
Alu sequence, was utilized to map cPLA2 to human chromo-
some lq25. Since this region also contains the functionally 
related prostaglandin synthase 2 gene, it was suggested that 
there may be coordinate regulation of cPLA2 and prostaglan-
din synthase 2. Upstream of the 5'-untranslated segment of 
the cDNA cloned earlier, a 5' exon of 136 nucleotides is 
separated by an intron of about 6 kb [16-18]. The 5' flanking 
region or the first exon contains exact or modified copies of 
sequence elements that may contribute to transcriptional reg-
ulation. There are no perfect TATA or CCA AT elements, but 
close homologs have been noted, along with a homolog of the 
Spl element [18]. In addition, there are consensus sites for 
N F K B , NF-IL-6, AP-1, AP-2, PEA3, OCT, C/EBP and 
GRE. While none of these elements has been shown experi-
mentally to regulate cPLA2 expression, one detailed study has 
revealed an important 27 bp poly-pyrimidine region immedi-
ately preceding the transcription start site [17]. This small 
region alone appears to support a significant amount of the 
total transcriptional activity of the cPLA2 gene, and may be 
responsible for the observed tight control that does not allow 
dramatic variation of the activity of this promoter [17]. The 
3'-untranslated region of the cPLA2 mRNA contains regions 
with increased AU content and multiple conserved AUUUA 
sequences that appear to regulate mRNA stability enhancing 
expression in mitogen-stimulated mesangial cells [19]. 
Although Southern blot analysis of human genomic DNA 
originally suggested the absence of genes closely related to 
cPLA2, it is quite likely that cPLA2 is a member of a larger 
family of structurally related enzymes. 
4. The cPLA2 protein 
The cPLA2 cDNA encodes a 749 amino acid protein with a 
predicted molecular mass of 85.2 kDa. The inferred sequence 
of murine cPLA2 is more than 95% homologous to the hu-
man cPLA2 sequence indicating great structural similarity be-
tween cPLA2 from different species. However, as shown in 
Fig. 1, the similarity between cPLA2 sequences from more 
evolutionarily distant species is reduced and reveals the less 
conserved regions that may serve as linkers between domains 
[11]. Three stretches of lesser identity are noteworthy: the 
region between Glu-163 and Ala-191, Leu-507 and Leu-521, 
as well as the C-terminal portion from Ala-711 to Ala-749. As 
further depicted in Fig. 1, the deduced cPLA2 protein sequen-
ces have several interesting structural features in common. 
First, the cPLA2 sequence contains a 68 amino acid stretch 
in the N-terminal portion termed CaLB domain that shows 
sequence homology with the C2 region of protein kinase C. 
This CaLB domain was also noted in the GTPase activating 
protein (GAP), phospholipase C and the synaptic vesicle pro-
tein p65. This domain was found to be responsible for the 
Ca2+-dependent binding of cPLA2 to membranes or phospho-
lipid substrate [21] and was recently crystallized [22]. Second, 
several essential amino acid residues have been identified that 
may be important for the catalytic mechanism of cPLA2. The 
cPLA2 sequence contains the segment Gly-Leu-Ser228-Gly-Ser 
that closely resembles the amino acid motif Gly-X-Ser-X-Gly 
present in many serine esterases and neutral lipases. The cen-
tral serine of this motif is known to serve as the active site 
nucleophile in these enzymes. Replacing Ser-228 with alanine 
(threonine or cysteine) by site-directed mutagenesis yielded 
correctly folded, but catalytically inactive cPLA2 thus demon-
strating that Ser-228 is required for the catalytic function of 
cPLA2 [23]. The role of Ser-228 as the active-site nucleophile 
was confirmed with novel substrates of cPLA2 and active-site 
directed inhibitors [24]. The Asp-549 of cPLA2 resides within 
a sequence motif (Ile-X-Val-Val-Asp-Ser-Gly-Leu-X-X-X-
Asn) that perfectly matches the specifications for catalytic 
aspartic acid residues in the subtilisin family of proteases. 
On mutation of Asp-549 to alanine (or asparagine or glutamic 
acid) the enzymatic activity of cPLA2 was abolished suggest-
ing that Asp-549 participates in the catalytic mechanism [25]. 
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Unlike other serine esterases and lipases, cPLA2 does not 
appear to have a histidine requirement for its catalytic func-
tion. Thus, all 19 His-to-Ala mutants of cPLA2 were found to 
exhibit significant enzymatic activity. The cPLA2 sequence 
contains nine free cysteine residues. Although the enzyme is 
readily inactivated by preincubation with the sulfhydryl re-
agent iV-ethylmaleimide (NEM), none of these cysteines was 
found to be essential for catalytic activity. However, only one 
of the cysteines, Cys-331, is responsible for the NEM sensi-
tivity and its substitution with alanine renders cPLA2 resistant 
to NEM. This indicates that Cys-331 may be located close to 
the active site. Third, the human cPLA2 sequence contains 
numerous diverse consensus phosphorylation sites for both 
serine/threonine and tyrosine protein kinases [15]. To date 
four serine residues were found to be phosphorylated in hu-
man cPLA2 overexpressed in cultured cells [26]. However, 
only two such sites, Ser-505 and Ser-727, are conserved in 
cPLA2 from other species. Ser-505 resides within the sequence 
Pro-Leu-Ser-Pro typically recognized by proline-directed kin-
ases, such as MAP kinases [27], and Ser-727 is flanked by 
arginines (Arg-Arg-(X)4-Arg-X-Ser-(X)8-Arg-Arg) typical of 
sites preferred by basotrophic kinases, such as protein kinase 
C and protein kinase A. Finally, other domains of interest 
include a 33 amino acid segment (residues 431^-63) in the 
middle of the sequence that is deficient in hydrophobic amino 
acids and may represent a flexible 'hinge' region. Moreover, 
the cPLA2 sequence contains a domain towards the C-termi-
nus (residues 520-680) modestly enriched in proline (~12% 
of total residues) that may be responsible for the abnormal 
electrophoretic mobility of cPLA2 on SDS polyacrylamide 
gels. 
5. Biochemical and catalytic properties of cPLA2 
Using in vitro enzyme assay systems cPLA2 was found to 
become catalytically active in the presence of 0.3-2 u,M Ca2+ 
as present in the cytosol of stimulated cells [10,11]. However, 
enzymatic activity of cPLA2 could be promoted by high salt 
in the absence of Ca2+ indicating that Ca2+ is not required for 
the catalytic activity of cPLA2 [28]. The salt effect is likely due 
to stimulation of hydrophobic interactions between cPLA2 
and phospholipids leading to its association with the substrate 
in the absence of Ca2+. cPLA2 preferentially cleaves arachi-
donic acid-containing phospholipids and hydrolyzes different 
l-stearoyl-2-arachidonoyl phospholipids with the order of 
preference phosphatidylcholine (PC) = phosphatidylinositol 
> phosphatidylethanolamine (PE) > phosphatidic acid = phos-
phatidylserine. With PC as substrate the fatty acid preference 
of cPLA2 was found to be arachidonic (20:4)>linolenic 
(18:3)>linoleic (18:2)>oleic (18:l)>palmitoleic (16:1) 
[29]. The order of preference among PCs containing 20-car-
bon sn-2 acyl chains was arachidonic (20:4) > homogammali-
noleic (20:3) > eicosadienoic (20:2) > eicosenoic (20:1) > eico-
sanoic (20:0) and there appeared to be a preference for 
positional isomers with double bonds closest to the sn-2 ester 
bond (eicosatrienoic 5,8,11 > 5,8,14 > 5,11,14 > 8,11,14). 
Although cPLA2 shows a marked preference for poly-unsatu-
rated long fatty acyl chains, its activity towards PE substrates 
decreased dramatically with chains longer and more unsatu-
rated than arachidonic acid (20:4) the order being arachidonic 
(20:4) > pentaenoic (20:5) > docosahexaenoic (C22:6) — O 
[30]. Interestingly, cPLA2 displays other catalytic activities 
and exhibited lysophospholipase and transacylase activities 
when incubated with lyso-LPC micelles [28]. However, incu-
bation of cPLA2 with PC containing dual-labeled fatty acids 
(l-palmitoyl-2-arachidonoyl-PC) revealed that the lysophos-
pholipase activity on newly formed 1-palmitoyl-lyso-PC was 
low. 
6. Activation of cPLA2 
cPLA2 is the only known PLA2 that exhibits functional 
properties indicative of a receptor-regulated PLA2 and is 
thus likely to be involved in receptor-mediated eicosanoid 
production and intracellular signal transduction processes. 
Studies from many different laboratories using different cellu-
lar systems have revealed that a wide spectrum of extracellular 
stimuli activate cPLA2 to mobilize PLA2 from cellular phos-
pholipids. These stimuli include growth factors, mitogens, vas-
oactive peptides, crosslinking of Fc receptors, integrin engage-
ment, cytokines and interferons. However, non-receptor-
mediated stimulation of cells by stressful stimuli, including 
oxidation, hyperglycemia, UV light and shear stress, may 
also promote cPLA2 activation. It is noteworthy that Ca2+ 
ionophores induce maximal release of arachidonic acid from 
cellular phospholipids suggesting that the increase in cytosolic 
free [Ca2+] is a predominant factor causing cPLA2 activation. 
Since cPLA2 binds to membranes in a Ca2+-dependent fash-
ion, increased cytosolic free Ca2+ mobilized from intracellular 
stores and/or derived from increased influx of extracellular 
Ca2+ is likely to induce the association of cPLA2 with cellular 
membranes. A wide variety of extracellular stimuli were found 
to cause rapid phosphorylation of cPLA2 suggesting that 
phosphorylation may also play an important role in the reg-
ulation of cPLA2 activation. In platelets, thrombin induced a 
time- and dose-dependent phosphorylation of cPLA2 that re-
sulted in enhanced catalytic activity, as well as a change in the 
electrophoretic and chromatographic properties of cPLA2 
[31]. By comparing the functional properties of cPLA2 from 
control and thrombin-stimulated platelets, it was found that 
while phosphorylated cPLA2 exhibited the same Ca2+ require-
ment and apparent substrate affinity (Km), its catalytic activity 
(J^ max) was increased compared to control cPLA2. The impor-
tance of this phosphorylation for the activation of cPLA2 as 
well as the identity of the involved kinase(s) have not been 
fully elucidated. An involvement of protein kinase C in the 
regulation of PLA2 has been demonstrated in some cells. 
However, in other cells down-regulation of protein kinase C 
did not affect the activation of cPLA2. In human platelets 
phosphorylation of cPLA2 induced by thrombin and collagen 
was not affected by specific inhibitors of protein kinase C 
demonstrating that platelet cPLA2 is phosphorylated by path-
ways independent of protein kinase C [32]. Early studies dem-
onstrated that cultured cells transfected with cPLA2 lacking 
the MAP kinase phosphorylation site (Ser505-Ala cPLA2) ex-
hibited diminished ability to release PLA2 in response to ag-
onists compared to control cells expressing comparable levels 
of unmutated cPLA2 [33]. Furthermore, studies with cultured 
cells and in vitro kinase assays showed that cPLA2 is a sub-
strate for the p42 MAP kinase (now referred to as ERK2). 
Many subsequent reports have proposed that phosphorylation 
of cPLA2 by ERK kinases is a critical step in the sequence of 
events leading to the mobilization of arachidonic acid in 
stimulated cells, but direct evidence to support this hypothesis 
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has not been provided. Unexpectedly, in human platelets 
stimulated with the thrombin receptor agonist peptide 
SFLLRN phosphorylation of cPLA2 occurred in the absence 
of ERK activation [34]. Furthermore, under conditions where 
ERK activation was completely suppressed, cPLA2 phospho-
rylation was unaffected [32]. Lastly, PD 098059, a specific 
inhibitor of the activation of ERKs did not block thrombin-
induced cPLA2 phosphorylation [35]. Taken together, these 
findings showed that in human platelets proline-directed kin-
ases distinct from the ERKs may be involved in the phosphor-
ylation of cPLA2. It was indeed observed that a recently dis-
covered stress-activated kinase, referred to as p38, is 
responsible for the phosphorylation of the Ser-505 site of 
platelet cPLA2 [36]. Surprisingly, however, prevention of the 
proline-directed phosphorylation of cPLA2 by specific inhib-
itors of p38 kinase did not affect its ability to rapidly mobilize 
PLA2 in stimulated platelets. These findings indicate that, at 
least in platelets, proline-directed phosphorylation is not a 
prerequisite for receptor-mediated activation of cPLA2. It is 
still possible that phosphorylation sites distinct from Ser-505 
of cPLA2 may be targeted by as yet unidentified kinases and 
it will be of great interest to further study their potential 
involvement in the regulation of cPLA2. 
7. Cellular localization of cPLA2 
Many different cell types contain cPLA2, including plate-
lets, macrophages, neutrophils, endothelial cells, vascular 
smooth muscle cells, alveolar epithelial cells, renal mesangial 
cells and keratinocytes. The cPLA2 gene is widely expressed 
and mRNA levels were most prominent in brain, lung, kid-
ney, heart and spleen [37]. Furthermore, using anti-cPLA2 
antibodies, the presence of cPLA2 protein was demonstrated 
in a variety of tissues from the guinea pig, in particular lung, 
spleen, brain and kidney [10]. Analysis of the subcellular dis-
tribution of cPLA2 in resting and stimulated cells indicated 
that upon cell activation cPLA2 redistributes from the cyto-
solic to the membrane fraction. Examination of the subcellu-
lar localization of cPLA2 in a variety of cells using immuno-
fluorescence microscopy showed that upon cell activation 
cPLA2 translocates to the endoplasmic reticulum and the nu-
clear membranes [38,39]. In subconfluent endothelial cells a 
significant portion of cPLA2 appears to reside within the nu-
cleus [40]. There is recent evidence demonstrating that pros-
taglandin synthase 1 and 2 are localized in the endoplasmic 
reticulum and in the nuclear envelope, respectively [41]. More-
over, 5-lipoxygenase translocates to a perinuclear site in 
stimulated cells [42]. It thus appears that in activated cells 
cPLA2 may be ideally positioned to provide free arachidon-
ic acid to the enzymes of the eicosanoid cascade. Further-
more, eicosanoids newly generated in close proximity to the 
nucleus can not only serve as agonists for cell surface recep-
tors, but may also target intracellular (nuclear) recognition 
sites. 
8. cPLA2 and disease 
Phospholipid breakdown and concomitant release of free 
fatty acids and lysophosphohpids, as well as production of 
eicosanoids and PAF are amongst the early events in the 
brain after global cerebral ischemia. Agents considered hall-
marks of ischemia and reperfusion, in particular the high in-
tracellular levels of free Ca2+ resulting from ischemic mem-
brane depolarization and opening of Ca2+ channels, are likely 
to trigger cPLA2 activation. Furthermore, pro-inflammatory 
cytokines such as IL-1 and TNF produced during ischemia 
are known to induce de novo synthesis of cPLA2 and may 
thus further potentiate the mobilization of PLA2 and subse-
quent production of eicosanoids and PAF. During global cer-
ebral ischemia (as typically observed during cardiac arrest) 
and mimicked in the four vessel occlusion model of ischemia 
in the rat, neurons of the hippocampal CA1 region of the 
brain are particularly sensitive to the ischemic insult and 
undergo a process of delayed cell death (also referred to as 
apoptosis) over a period of days after the ischemia. Biochem-
ical analyses, including immunoblotting and enzymatic assay, 
showed elevated levels of cPLA2 in ischemic compared to 
control hippocampal tissues [43]. Furthermore, immunohisto-
chemical analysis of brain sections from rats subjected to is-
chemia demonstrated a marked induction of cPLA2 in the 
CA1 hippocampal region. Notably, this immunoreactivity 
was confined to astrocytes and microglia in areas of neuro-
degeneration. Recent studies with cellular systems have docu-
mented that the increase in cellular eicosanoid production 
promoted by cytokines and agents causing cell damage is, at 
least in part, due to activation of cPLA2 and elevation of its 
cellular levels [44]. It was also found that cPLA2 is a target of 
anti-inflammatory glucocorticoids well-known for their ability 
to attenuate eicosanoid synthesis in a number of different cell 
types. Thus, it has become clear that cPLA2 may play an 
important role in both the rapid and the prolonged cellular 
responses occurring during inflammatory and degenerative 
processes. 
9. Conclusions 
The Ca2+-sensitive 85 kDa cytosolic PLA2 (cPLA2) is acti-
vated by receptor-mediated events and stressful stimuli and 
initiates the cascade of events leading to the production of 
free fatty acids, lysophosphohpids, eicosanoids and PAF. Ac-
tivation of cellular cPLA2 is clearly dependent on an increase 
in cytosolic free [Ca2+] to allow for association of cPLA2 with 
the membrane phospholipid substrate and, in some cellular 
systems, may also require phosphorylation of cPLA2 by stim-
ulus-activated kinases. Cellular mobilization of arachidonic 
acid and eicosanoid production are hallmarks of inflamma-
tion, and increased eicosanoids mediate both pathophysiolog-
ical alterations and cellular processes which lead to inflamma-
tory injury. There is substantial evidence to indicate that 
cPLA2 may be an important component in the cascade of 
events leading to the production of pro-inflammatory and 
injurious mediators in inflammatory and degenerative disease 
states. Accordingly, cPLA2 is an attractive target for the de-
velopment of novel therapies. 
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